HER2 / CEP17 Ratio as Biomarker for Complete Response in Neoadjuvant Therapy with Trastuzumab.
In a recent study, HER2-overexpressing early breast cancer patients who had received neoadjuvant trastuzumab were included to evaluate whether pathologic complete response (pCR) to neoadjuvant trastuzumab is dependent on the level of HER2 amplification. Absolute HER2 and chromosome 17 centromere (CEP17) were measured by in situ hybridization analysis, and associations were examined between HER2/CEP17 ratio […]
